Pradaxa Tops FDA Death Reports As Judge Rules Lawsuits Will Stand

Share Article

The Pradaxa Resource Center is the Web’s largest source for information on Pradaxa research, side effects and legal news. Visit http://www.Pradaxa-lawsuits.org

Pradaxa Diagram
Anyone who has suffered internal bleeding or had a loved one affected by taking Pradaxa is encouraged to speak with a lawyer about their legal rights as soon as possible.

The patient advocates at the Pradaxa Resource Center are alerting those who have been prescribed the blood thinner Pradaxa that the drug has been associated with severe internal bleeding. Those affected are advised that a federal judge recently ruled cases against the manufacturer can proceed.

Anyone who has suffered internal bleeding or had a loved one affected by taking Pradaxa is encouraged to speak with a lawyer about their legal rights as soon as possible.

Pradaxa is a popular anticoagulant drug prescribed to stop strokes and blood clots in patients with atrial fibrillation. Although only on the market since October, 2010, the drug has earned over $1 billion for manufacturer Boehringer Ingelheim in the year ending February, 2012, according to a Wall Street Journal report on April 24, 2012.

On December 7, 2011, however, the FDA warned that it would launch an investigation after receiving more injury or death reports from Pradaxa than expected. This came after Reuters reported in November that the drug maker admitted receiving more than 260 reports of internal bleeding death among users.

Recently, the Institute for Safe Medication Practices reported on June 6, 2012 that Pradaxa led all other medications in 2011 for reports of death or bleeding to the FDA.

Due to the number of Pradaxa lawsuits expected over bleeding or death, a federal panel recently established a central court in Illinois to handle the claims. The case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

On July 25th, Judge David Herndon, who will oversee the litigation, issued an order denying attempts by Boehringer Ingelheim to dismiss Pradaxa bleeding lawsuits. He ruled that, although the manufacturer warned of internal bleeding, this did not address the risk of uncontrollable bleeding and the lack of a reversal agent.

Now that the cases may proceed, anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options. Victims should only choose someone with experience in this type of litigation. The Pradaxa Resource center works only with lawyers who are already handling Pradaxa lawsuits.

For more information on the research, warnings, Pradaxa side effects and legal options relating to the drug Pradaxa, or to speak with a lawyer, visit http://www.Pradaxa-lawsuits.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patient Advocate
Visit website